TY - JOUR
T1 - The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
AU - Singh, Sima
AU - Numan, Arshid
AU - Maddiboyina, Balaji
AU - Arora, Saahil
AU - Riadi, Yassine
AU - Md, Shadab
AU - Alhakamy, Nabil A.
AU - Kesharwani, Prashant
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/7
Y1 - 2021/7
N2 - Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.
AB - Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.
UR - https://www.scopus.com/pages/publications/85103129881
U2 - 10.1016/j.drudis.2021.03.011
DO - 10.1016/j.drudis.2021.03.011
M3 - Review article
C2 - 33745879
AN - SCOPUS:85103129881
SN - 1359-6446
VL - 26
SP - 1721
EP - 1727
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 7
ER -
